---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004753"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T20:51:02.601907+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia Pharma Q4 NUPLAZID sales $136.5M, full-year $517.2M; PDUFA for trofinetide March 12

## Summary
- Net sales $517.2M in 2022, up 7% YoY; Q4 sales $136.5M, up 4% YoY.
- Net loss $216.0M for 2022 vs $167.9M in 2021; Q4 loss $41.7M ($0.26/share).
- PDUFA action date March 12, 2023 for trofinetide for Rett syndrome.
- 2023 guidance: NUPLAZID sales $520-550M; R&D $235-255M; SG&A $360-380M.
- Doug Williamson appointed EVP Head of R&D in Jan 2023; Serge Stankovic retired.

## SEC filing metadata
- accession: 0000950170-23-004753
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/acad-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004753
- JSON: https://secwatch.observer/filing/0000950170-23-004753.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004753.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported financial results for the full year ended December 31, 2022.
  - Period: the full year ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.